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OBJECTIVES: There has been recent controversy regarding the effectiveness of
vertebral augmentation (balloon kyphoplasty (BKP) and vertebroplasty (VP)) for
treating vertebral compression fractures (VCFs). Limited cost comparisons of BKP
and VP suggest that initial hospital costs are higher for BKP (Mehio 2011), however
costs for subsequent post-operative care are unknown. The present study sought
to characterize and compare the treatment costs for BKP and VP patients through
2 years post-surgery.METHODS:Using the 2005-2009 5%Medicare claims data, BKP
and VP patients were identified using ICD-9-CM and CPT-4 codes. Treatment costs
(Medicare reimbursement/payment adjusted to June 2011 dollars) were compiled
for all components of treatment during the 2-year follow-up. Length of stay (LOS)
and treatment costs for BKP and VP patients were compared using logistic regres-
sion, adjusting for gender, age, census region, comorbidities (Charlson score), race,
socio-economic status (Medicare buy-in status), cancer diagnosis (presence in prior
12 months) and year of surgery. RESULTS: A final cohort of 2878 BKP and 1,609 VP
patients was included. LOS was 3.5 / 4.1 days and 5.5 / 4.3 days for BKP and
VP patients who had inpatient procedures, corresponding to 43% shorted LOS (ad-
justed) for BKP (p0.001). There were no significant differences in average adjusted
treatment costs for BKP and VP patients within the first 3 (p0.097) and first 6
months (p0.142). For the remaining periods, however, BKP patients had lower
adjusted costs (p0.025). At 2 years, the average adjusted costs were 7% lower for
BKP (p0.005). CONCLUSIONS: Although BKP and VP patients in the Medicare pop-
ulation were found to have similar treatment costs within the first six months
following surgery, BKP was found to be cost saving compared to VP subsequently
over time through 2 years.
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OBJECTIVES: To compare clinical and economic outcomes of patients with bone
fracture nonunion receiving non-invasive electrical bone growth stimulator
(EBGS), low-intensity pulsed ultrasound stimulator (LIPUS), or neither stimulation
(No-stim) treatment. METHODS: Medical and pharmacy claims from a U.S. com-
mercially-insured population were analyzed to select patients aged65 who were
newly diagnosedwith nonunion fracture between July 2006 to September 2009. The
date of receiving the first nonunion diagnosis was set as the index date. Three
cohorts were constructed based on the first treatment patients received within
one-year after the index date: EBGS, LIPUS or No-stim. Baseline demographic and
clinical characteristics, and healthcare costs during 9 months before and 1 year
after the index date were assessed. Multivariate regression analyses were per-
formed to compare health care costs incurred in one-year after the index date
between cohorts. RESULTS: A total of 11,628 patients with nonunion fracture
(mean age 45.4 years; 46% males) were identified (EBGS: 29.5%, LIPUS: 12.3%, No-
stim: 58.2%). More than half of the patients (51.8%) had facture-related treatments
in one-year after the index date, and EBGS patients had lower proportion than
LIPUS (37.0% vs. 45.1% , p0.01) and No-stim cohorts (37.0% vs. 60.7%, p0.01).
Patients receiving EBGS were less likely to have at least one hospitalization during
one-year post-index period (14.8% vs. 19.5%, and 14.8% vs. 23.9%, both p0.01).
EBGS cohort had statistically significant lower health care costs in 1-year after
index date than LIPUS (mean: $20,743 vs. $23,271, p0.01) and No-stim cohorts
(mean: $20,743 vs. $24,315, p0.01). Adjusting for variables such as demographic
and clinical characteristics, EBGS patientsmaintained their statistically significant
lower health care costs in one-year after the index date than LIPUS (predicted costs:
$21,632 vs. $23,964, p0.01) and No-stim cohorts (predicted costs: $21,632 vs.
$23,843, p0.01). CONCLUSIONS: Nonunion fracture patients receiving non-inva-
sive electronic stimulation had lower health care costs than patients receiving
ultrasound stimulation or no stimulation.
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OBJECTIVES: Endometrial ablation has emerged as a minimally invasive alterna-
tive to hysterectomy for pre-menopausal patients suffering from menorrhagia.
Less invasive ablation procedures include thermal balloon endometrial ablation
using GYNECARE THERMACHOICE® III (Ethicon, Inc.), and radio-frequency endo-
metrial ablation using NovaSure® (Hologic, Inc.). This study compares costs of
achieving desired treatment outcomes with Thermachoice versus Novasure abla-
tion techniques.METHODS: A value analysis model was developed to estimate the
cost-per-patient treated with either device – overall, and for achieving desired
treatment outcomes of ‘amenorrhea’, ‘return to normal bleeding’, and ‘patient
satisfaction’. Subsequent hysterectomy was also modeled as a failure outcome.
Costs were included for the ablation device, disposables, operating room (OR) time,
and subsequent hysterectomy. Capital expenditure for controller was included for
Thermachoice, but not for Novasure, to represent a best possible scenario for No-
vasure. Analysis was performed from a hospital buyer perspective, over 1- and 3-
years following initial ablation procedure. Sensitivity analyses were conducted by
forcing reductions in clinical effectiveness and simultaneous increase in subse-
quent hysterectomy for procedure with lesser costs in the base cases. RESULTS:
100 hypothetical patients underwent each procedure. Overall cost-per-patient was
lower for Thermachoice over both 1 and 3 year timeframes – offering a saving of
about 4% compared toNovasure. For specific outcomes, savingswere between 6.9%
for ‘patients achieving amenorrhea’ to 7.8% for ‘patients returning to normal bleed-
ing’ in 1 year and between 3.8% and 4.8% for all outcomes in the 3 year scenario.
Sensitivity analyses showed that Thermachoice continued to offer savings in over-
all cost-per-patient compared to Novasure even with a reduction of all effective-
ness outcomes and increase in subsequent hysterectomy rates by about 50% and
18% in the 1- and 3-year scenarios. CONCLUSIONS: In our model, endometrial
ablation with Thermachoice offered cost savings – compared to Novasure, in
achieving desired short and long term treatment outcomes.
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OBJECTIVES: There is controversy regarding the most appropriate method to ana-
lyze cost data. We examined the role of censoring, model fit and assumption vio-
lations in a study determining the costs of dialysis modality for the treatment of
kidney failure.METHODS: All incident dialysis patients from Alberta from 1999 to
2003 were tracked for direct medical costs (inpatient and outpatient costs, physi-
cian claims, and medication costs) for three years using administrative datasets,
and categorized into peritoneal dialysis (PD) only, hemodialysis (HD) only, or mo-
dality switches (HD to PD; PD to HD). Unadjusted censored and uncensored cumu-
lative costs were determined using the non-parametric method of Lin and boot-
strapping. Model fit and assumption violations for alternate covariate adjusted
regression models were assessed through comparison of various approaches (OLS
or GLM regression, log-transformation, smearing), and the optimal approach
identified. RESULTS: Three year adjusted cumulative costs for patients receiving
PD only and HD to PD groups were $58,724 ($44,123-$73,325; 95% confidence inter-
val) and $114,503 ($96,318-$132,688) respectively, andwere significantly lower than
patients receiving HD only $175,996 ($134,787-$217,205) and PD technique failure
patients $173,308 ($147,725-$119,891). Comparison of censored and uncensored
unadjusted total cumulative costs yielded similar results. Covariate adjusted GLM
regression was the best fit for modeling total cumulative costs when compared to
otherOLS andGLMmodels. For cost categorieswith smaller sample sizes (inpatient
costs; n674), GLM models fitted poorly due to kurtosis, and OLS regression on
log-transformed costs with smearing yielded better less biased estimates.
CONCLUSIONS: GLM regression methods for estimating costs performed well
when applied to our analyseswith larger datasets (n1000), but gave biased results
when smaller datasetswere used.Whenmodeling costswith smaller sample sizes,
the most appropriate regression method can be determined through model diag-
nostics.
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OBJECTIVES: The purpose of this study was to estimate the cost of chest X-ray by
activity based costing approach. METHODS: Study was conducted at radiology
department, Penang General Hospital, Penang, Malaysia. The activities involved in
producing a chest X-ray in the hospital were first identified through interviewwith
key personnel in the radiology department. Human resource costwas calculated by
multiplying the mean time spent (in minutes) by employees doing specific activity
to their per-minute salaries. The costs of consumables and clinical equipments
were obtained from the procurement section of the radiology department. The cost
of the building was calculated by multiplying the area of space used by the chest
X-ray facility with the unit cost of public building department. Moreover, straight-
line deprecation with a discount rate of 3% was assumed for calculation of equiv-
alent annual costs for building and machines. Cost of electricity was calculated by
multiplying number of kilo watts used by electrical appliance (chest X-ray facility)
in the year 2010 with electricity tariff for Malaysian commercial consumers (MYR
0.31 per kWh). RESULTS: Five activities were identified which were required to
develop one chest X-ray film. Human resource, capital, consumable and electricity
cost was MYR 1.48, MYR 1.98, MYR 2.15 and MYR 0.04, respectively. Total cost of
single chest X-ray was MYR 5.65 (USD 1.75). CONCLUSIONS: By applying ABC ap-
proach, we can havemore detailed and precise estimate of cost for specific activity
or service. Choice of repeating a chest X-ray for a patient can be based on our
findings, when cost is a limiting factor.
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OBJECTIVES: Refractory overactive bladder (OAB) with urge incontinence is an
underdiagnosed condition with substantial burden on the health care system and
patients with diminished quality-of-life. A significant number of patients will fail
conservative treatment with optimized medical-therapy (OMT) and may benefit
from minimally invasive procedures including sacral-neuromodulation (SNM) or
botulinum-toxin (BonT-A). The goal of this study was to estimate the cost-effec-
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